US5690910A - Method for treating asthma - Google Patents
Method for treating asthma Download PDFInfo
- Publication number
- US5690910A US5690910A US08/516,786 US51678695A US5690910A US 5690910 A US5690910 A US 5690910A US 51678695 A US51678695 A US 51678695A US 5690910 A US5690910 A US 5690910A
- Authority
- US
- United States
- Prior art keywords
- ulmwh
- antigen
- molecular weight
- composition
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000000427 antigen Substances 0.000 claims abstract description 70
- 102000036639 antigens Human genes 0.000 claims abstract description 63
- 108091007433 antigens Proteins 0.000 claims abstract description 63
- 229940127215 low-molecular weight heparin Drugs 0.000 claims abstract description 17
- 230000001684 chronic effect Effects 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 230000037396 body weight Effects 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 32
- 239000000443 aerosol Substances 0.000 claims description 11
- 230000014508 negative regulation of coagulation Effects 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000006199 nebulizer Substances 0.000 claims description 3
- 239000003380 propellant Substances 0.000 claims description 3
- 150000004044 tetrasaccharides Chemical class 0.000 claims description 3
- 150000004043 trisaccharides Chemical class 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 239000004479 aerosol dispenser Substances 0.000 claims description 2
- 230000003385 bacteriostatic effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 abstract description 31
- 230000010085 airway hyperresponsiveness Effects 0.000 abstract description 31
- 238000011282 treatment Methods 0.000 abstract description 10
- 229920000669 heparin Polymers 0.000 description 44
- 229960002897 heparin Drugs 0.000 description 41
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 31
- 229940087051 fragmin Drugs 0.000 description 31
- 230000000694 effects Effects 0.000 description 26
- 206010006482 Bronchospasm Diseases 0.000 description 18
- 230000000172 allergic effect Effects 0.000 description 16
- 208000010668 atopic eczema Diseases 0.000 description 16
- 241001494479 Pecora Species 0.000 description 14
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 12
- 230000036427 bronchial hyperreactivity Effects 0.000 description 12
- 230000007885 bronchoconstriction Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 8
- 229960004484 carbachol Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000002565 heparin fraction Substances 0.000 description 7
- 239000003055 low molecular weight heparin Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 208000009079 Bronchial Spasm Diseases 0.000 description 6
- 208000014181 Bronchial disease Diseases 0.000 description 6
- 239000004044 bronchoconstricting agent Substances 0.000 description 6
- 230000003435 bronchoconstrictive effect Effects 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108700025647 major vault Proteins 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 102000004411 Antithrombin III Human genes 0.000 description 3
- 108090000935 Antithrombin III Proteins 0.000 description 3
- 208000037883 airway inflammation Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 229960005348 antithrombin iii Drugs 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000244188 Ascaris suum Species 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000001858 anti-Xa Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 206010001382 Adrenal suppression Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003557 Asthma exercise induced Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical group N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Definitions
- the invention relates to methods and compositions for preventing and reversing the symptoms and manifestations of asthma.
- Chronic asthma can be considered to be predominantly an inflammatory disease with associated bronchospasm.
- the degree of reactivity and narrowing of the bronchi in response to stimuli is greater in asthmatics than in normal individuals. Persistent inflammation is responsible for the bronchial hyperreactivity or airway hyperresponsiveness. Mucosal edema and mucus plugging and hypersecretion may be present; pulmonary parenchyma is normal. Airway narrowing may reverse spontaneously or with therapy.
- Type 1 (immediate) immune responses may play an important role in the development of asthma in children and many adults; however, when onset of disease occurs in adulthood, allergic factors may be difficult to identify. Exposure to cold dry air, exercise and other aggravating factors also may trigger asthma.
- Beta agonists are useful as bronchodilator agents; they stimulate beta 2 -adrenergic receptors, increase intracellular cAMP, and may inhibit the release of mast cell mediators.
- Other useful drugs include theophylline and related xanthine drugs, which produce bronchodilation through unknown mechanisms; the biscromone, cromolyn, which prevents the release of mediator substances and blocks respiratory neuronal reflexes, and corticosteroids, which primarily decrease inflammation and edema.
- Anticholinergic drugs may relieve bronchospasm by blocking parasympathetic cholinergic impulses at the receptor level.
- Antihistamines occasionally prevent or abort allergic asthmatic episodes, particularly in children, but they can only be partially effective in asthma because histamine is only one of many mediators.
- the current drug modalities used for treatment of allergy-induced asthma suffer from a number of drawbacks.
- the conventional agents have a relatively short duration of action and may be partially or wholly ineffective when administered after antigen challenge occurs.
- agents such as beta 2 -adrenergic agonists and corticosteroids
- the therapeutic margin of safety with such agents is relatively narrow and patients using them must be carefully monitored.
- Bronchial hyperreactivity is a hallmark of asthma and is closely related to underlying airway inflammation. Worsening of asthma and airway inflammation is associated with increase in bronchial hyperreactivity, which can be induced by both antigenic and non-antigenic stimuli.
- Beta 2 -adrenergic agonists are potent agents for the treatment of bronchospasm, but have no effect on airway inflammation or bronchial hyperreactivity. In fact, chronic use of beta 2 -adrenergic agents alone, by causing down regulation of beta 2 -receptors, may worsen bronchial hyperreactivity.
- corticosteroids are the only effective agents available which diminish bronchial hyperreactivity. Although inhaled corticosteroids are relatively safe in adult patients with asthma, these agents have tremendous toxicity in children, including adrenal suppression and reduced bone density and growth. Thus, the search for safer and effective agents which diminish bronchial hyperreactivity continues.
- heparin administered intrabronchially can be an effective inhibitor of bronchospasm and bronchoconstriction and is consequently of value in the prophylaxis of asthma (see, e.g., Ahmed et al., New Eng. J. Med., 329:90-95, 1993; Ahmed, Resp. Drug Deliv., IV:55-63, 1994).
- low molecular weight heparins e.g., heparins with an average molecular weight of 4,000-5,000 daltons
- these low-weight heparins also exhibit considerably less anticoagulant activity than commercial heparin, a desirable property when these agents are used in the treatment of asthma (see Ashkin et al., Am. Rev. Resp. Dis., 1993 Intl. Conf. Abstracts, p. A660).
- Still another object of the present invention is to provide a method and compositions as described above which are highly effective in diminishing specific and non-specific bronchial hyperreactivity, and even when administered after antigen challenge to the patient.
- the invention resides in a method of treating a patient suffering from antigen-induced asthma through the intrabronchial administration to the patient of a pharmaceutical composition comprising from about 0.05 to about 1.0 mg of ultra-low molecular weight heparins per kilogram of patient body weight in each dose.
- the administration of these heparins can be on an acute basis following antigen challenge or on a chronic basis to suppress bronchial hyperreactivity.
- the ultra-low molecular weight heparins used in the present invention have average molecular weights of less than 3,000 daltons and may exhibit a low level of anticoagulant activity or substantially no anticoagulant activity at all.
- Novel inhalant compositions are also provided in the form of liquid or powdered nebulizer or aerosol compositions containing suitable concentrations of ultra-low molecular weight heparins.
- FIG. 1 is a bar graph illustrating the effect of pretreatment with inhaled ultra-low molecular weight heparin (CY222) at varying dose levels on antigen-induced acute bronchoconstriction in allergic sheep. Data are shown as antigen-induced mean ⁇ SE % change in SR L , without and after pretreatment with CY222.
- CY222 inhaled ultra-low molecular weight heparin
- FIG. 2 is a bar graph illustrating the effect of pretreatment with inhaled low molecular weight heparin (CY216) on antigen-induced acute bronchoconstriction in allergic sheep. Data are shown as antigen-induced mean ⁇ SE % change in SR L , without and after pretreatment with CY216.
- CY216 inhaled low molecular weight heparin
- FIG. 3 is a bar graph illustrating the effect of pretreatment with inhaled medium molecular weight heparin (Fragmin) on antigen-induced bronchoconstriction in allergic sheep. Data are shown as antigen-induced mean ⁇ SE % change in SR L , without and after treatment with Fragmin.
- Fragmin medium molecular weight heparin
- FIG. 4 is a bar graph illustrating the effect of pretreatment with inhaled ultra-low molecular weight heparin (CY222) on antigen-induced airway hyperresponsiveness in allergic sheep. Data are shown as post-antigen mean ⁇ SE PD 4 , as percentage of baseline, without and after pretreatment with CY222.
- PD 4 Cumulative provocating dose of carbachol, increasing SR L to 400% above baseline
- FIG. 5 is a bar graph illustrating the effect of pretreatment with inhaled low molecular weight heparin (CY216) on antigen-induced airway hyperresponsiveness in allergic sheep. Data are shown as post-antigen mean ⁇ SE PD 4 , as percentage of baseline, without and after pretreatment with CY216.
- FIG. 6 is a bar graph illustrating the effect of pretreatment with inhaled medium molecular weight heparin (Fragmin) on antigen-induced airway hyperresponsiveness in allergic sheep. Data are shown as post-antigen mean ⁇ SE PD 4 , as percentage of baseline, without and after pretreatment with Fragmin.
- Fragmin medium molecular weight heparin
- FIG. 7 is a graph illustrating the comparative protective effects of inhaled CY222, CY216 and Fragmin on antigen-induced acute bronchoconstrictor response (ABR) in allergic sheep. Data are shown as post-antigen mean ⁇ SE % protection of antigen-induced ABR. Thick horizontal bars represent ID 50 .
- FIG. 8 is a graph illustrating the comparative protective effects of inhaled CY222, CY216 and Fragmin on antigen-induced airway hyperresponsiveness (AHR) in allergic sheep. Data are shown as post-antigen mean ⁇ SE % protection of antigen-induced changes in PD 4 .
- FIG. 9 is a bar graph illustrating the effect of CY222 on antigen-induced airway hyperresponsiveness with CY222 being administered as an aerosol immediately after antigen challenge.
- FIG. 10 is a bar graph illustrating the effect of commercial heparin on antigen-induced airway hyperresponsiveness with commercial heparin being administered as an aerosol immediately after antigen challenge.
- FIG. 11 is a bar graph illustrating the effect of Fragmin on antigen-induced airway hyperresponsiveness with Fragmin being administered as an aerosol immediately after antigen challenge.
- Heparin a sulfated mucopolysaccharide
- Heparin is synthesized in mast cells as a proteoglycan and is particularly abundant in the lungs of various animals.
- Heparin is not a specific compound of fixed molecular weight but is actually a heterogenous mixture of variably sulfated polysaccharide chains composed of repeating units of D-glucosamine and either L-iduronic or D-glucuronic acids.
- the average molecular weight of heparin isolated from animal tissues ranges from about 6,000 to about 30,000 daltons.
- heparin is known primarily as an anticoagulant. This activity results from heparin's ability to bind to some of the residues of antithrombin III (AT-III), accelerating the neutralization by AT-III of activated clotting factors and preventing the conversion of prothrombin to thrombin. Larger amounts of heparin can inactivate thrombin and earlier clotting factors, preventing conversion of fibrinogen to fibrin.
- AT-III antithrombin III
- the anticoagulant activity of heparin is related to the molecular weight of its polysaccharide fragments; low molecular weight components or fragments (for example, fragments having a molecular weight of less than 6,000 daltons) have moderate to low antithrombin and hemorrhagic effects. Similarly, low molecular weight heparins isolated from animal tissue have reduced anticoagulant properties because they consist primarily of the lower molecular weight fragments or fractions.
- heparin which is generally derived from beef lung or pork intestinal mucosa, has an average molecular weight of about 15,000-17,500 daltons.
- Heparin has been shown to act as a specific blocker of the IP 3 receptors and inhibits IP 3 mediated calcium release. We have previously suggested that heparin may block IP 3 receptors in mast cells and therefore by interfering with signal transduction may modulate mast cell degranulation and mediator release. In vivo and in vitro studies support this concept and have demonstrated that inhaled heparin can attenuate allergic bronchoconstriction in sheep, prevent exercise induced asthma, as well as inhibit anti IgE induced mast cell histamine release. Inhaled heparin in doses up to 1,000 units/kg has been found to have no effect on partial thromboplastin time (PTT), thus, suggesting a "non-anticoagulant" effect.
- PTT partial thromboplastin time
- ultra-low molecular weight heparin (ULMWH) fractions are not only effective inhibitors of airway anaphylaxis, but are highly effective in reducing AHR even when administered after antigen challenge.
- ULMWH ultra-low molecular weight heparin
- the present invention constitutes a method of treating a patient suffering from antigen-induced asthma who has been challenged with an asthma-inducing antigen comprising the intrabronchial administration to the patient of a pharmaceutical composition containing about 0.05 to about 1.0 mg of one or more ULMWH fractions per kilogram of patient body weight in each dose of said composition, and preferably from about 0.075 to about 0.75 mg/kg per dose.
- ULMWH may be defined as heparin fractions having an average molecular weight of 3,000 daltons or less. ULMWH having an average molecular weight of 2,500 daltons or less may be even more effective when used in the method of the invention.
- Each ULMWH fraction may comprise disaccharides, trisaccharides, tetrasaccharides and/or pentasaccharides, as well as molecules of greater chain length.
- the invention also comprehends the chronic administration of ULMWH to asthma patients to reduce and suppress AHR.
- Chronic administration refers to administration of the ULMWH-containing compositions at least once daily for at least ten consecutive days.
- Chronic administration of a composition containing from about 0.05-1.0 mg/kg per dose, and preferably about 0.075-0.75 mg/kg per dose, can be continued indefinitely to provide AHR-suppressant therapy at least comparable to corticosteroids but substantially without side effects.
- ULMWH fractions which are active and can be used in the present invention for treating asthmatic patients are all N-sulfated; N-desulfated fractions are ineffective.
- the inhalant ULMWH compositions used in the present invention may comprise liquid or powdered compositions containing ULMWH and suitable for nebulization and intrabronchial use, or aerosol compositions administered via an aerosol unit dispensing metered doses.
- Suitable liquid compositions comprise ULMWH in an aqueous, pharmaceutically acceptable inhalant solvent, e.g., isotonic saline or bacteriostatic water.
- the solutions are administered by means of a pump or squeeze-actuated nebulized spray dispenser, or by any other conventional means for causing or enabling the requisite dosage amount of the liquid composition to be inhaled into the patient's lungs.
- Suitable powder compositions include, by way of illustration, powdered preparations of heparin thoroughly intermixed with lactose or other inert powders acceptable for intrabronchial administration.
- the powder compositions can be administered via an aerosol dispenser or encased in a breakable capsule which may be inserted by the patient into a device that punctures the capsule and blows the powder out in a steady stream suitable for inhalation.
- Aerosol formulations for use in the subject method would typically include fluorinated alkane propellants, surfactants and co-solvents and may be filled into aluminum or other conventional aerosol containers which are then closed by a suitable metering valve and pressurized with propellant.
- the total concentration of ULMWH fractions in any vehicle suitable for use in accordance with the present invention must be sufficiently high to provide the required dose of about 0.05 to 1.0 mg of ULMWH/kg.
- concentration of ULMWH in the solution in the case of a patient weighing 75 kg should be approximately 1.0-20.0 mg/ml.
- the ULMWH compositions described herein provide highly effective treatment for antigen-induced asthma even after antigen challenge has occurred.
- the ULMWH utilized in this experiment not only has a molecular weight well below 3,000, but in addition about 88% of the heparin chains included in this fraction have molecular weights below 2,500.
- PD 4 airway responsiveness
- SR L was measured, before and immediately after challenge, and then hourly for up to 2 hours until SR L had returned to the baseline.
- the post-challenge PD 4 was then measured.
- the protocol was repeated at least 14 days later, after pretreatment with aerosolized CY222, CY216, and Fragmin, at doses of 0.31, 0.62, 1.25, 2.5, and 5.0 mg/kg.
- Pretreatment with aerosolized CY222, CY216, and Fragmin attenuated the antigen-induced AHR in a dose dependent fashion; the minimal effective doses were 0.62 mg/kg, 1.25 mg/kg, and 5.0 mg/kg; respectively.
- the ULMWH fraction, CY222 was the most potent agent, as shown by significant inhibition of antigen-induced bronchoconstriction and AHR at 0.6 mg/kg dose, while CY216 and Fragmin were ineffective at this dose.
- the group average values of I.D. 50 of CY222, CY216 and Fragmin against allergic bronchoconsriction were 0.5, 1.3 and 1.8 mg/kg, respectively.
- the respective group average values of I.D. 50 of CY222, CY216 and Fragmin against AHR were 0.51, 2.5 and 4.7 mg/kg.
- Example II The same experimental protocol was followed as in Example I, except that (a) the three heparin materials administered to the test animals were CY222, commercial heparin (molecular weight approximately 15,000 daltons) and Fragmin, and (b) the heparins were administered to the animals as an aerosol immediately after antigen challenge.
- the test data are set forth in Table 7 and graphically illustrated in FIGS. 9-11.
- inhaled CY222 administered after antigen challenge substantially modified post-antigen AHR, restoring AHR levels in the test subjects to baseline levels or above. This effect was not observed with commercial heparin or Fragmin, wherein no improvement in AHR resulted from post-challenge administration of these heparins.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/516,786 US5690910A (en) | 1995-08-18 | 1995-08-18 | Method for treating asthma |
IL12316696A IL123166A (en) | 1995-08-18 | 1996-08-13 | A pharmaceutical preparation containing sections of heparin N-sulfate with a very low molecular weight for short-term treatment |
JP50942897A JP3263723B2 (ja) | 1995-08-18 | 1996-08-13 | 喘息を治療するための組成物、及び喘息にかかった患者を治療するための気管支内薬物の製造における超低分子量ヘパリンの使用 |
AU66945/96A AU701691B2 (en) | 1995-08-18 | 1996-08-13 | Method and composition for treating asthma |
DE69635023T DE69635023T2 (de) | 1995-08-18 | 1996-08-13 | Ulmwh (ultra-low-molecular weight heparin) zur behandlung von asthma |
KR10-1998-0701167A KR100451901B1 (ko) | 1995-08-18 | 1996-08-13 | 항원-유도성천식환자치료및기도과민반응을감소,억제시키기위한제약학적조성물 |
PL96324970A PL186912B1 (pl) | 1995-08-18 | 1996-08-13 | Zastosowanie i kompozycja do leczenia astmy |
ES96926952T ES2244974T3 (es) | 1995-08-18 | 1996-08-13 | Ulmwh (heparina de peso molecular ultrabajo) para tratar asma. |
HU9901614A HUP9901614A3 (en) | 1995-08-18 | 1996-08-13 | Use of ultra-low molecular weights heparins for preparing pharmaceutical compns. for treting asthma |
CA002229060A CA2229060A1 (en) | 1995-08-18 | 1996-08-13 | Method and composition for treating asthma |
AT96926952T ATE300938T1 (de) | 1995-08-18 | 1996-08-13 | Ulmwh (ultra-low-molecular weight heparin) zur behandlung von asthma |
PCT/US1996/013133 WO1997006783A1 (en) | 1995-08-18 | 1996-08-13 | Method and composition for treating asthma |
DK96926952T DK0844869T3 (da) | 1995-08-18 | 1996-08-13 | ULMWH (heparin med ultralav molekylvægt) til behandling af astma |
PT96926952T PT844869E (pt) | 1995-08-18 | 1996-08-13 | Hubpm (heparina de ultra-baixo peso molecular) para tratamento da asma |
CZ1998481A CZ292134B6 (cs) | 1995-08-18 | 1996-08-13 | Farmaceutický přípravek pro léčbu pacienta trpícího astmatem a použití heparinů o ultranízké molekulové hmotnosti |
SK172-98A SK282759B6 (sk) | 1995-08-18 | 1996-08-13 | Farmaceutická kompozícia na liečbu astmy |
NZ315275A NZ315275A (en) | 1995-08-18 | 1996-08-13 | Inhalant composition including ultra low mw heparins (ULMWH) to treat asthma |
ZA9606838A ZA966838B (en) | 1995-08-18 | 1996-08-13 | Method and composition for treating asthma. |
EP96926952A EP0844869B1 (en) | 1995-08-18 | 1996-08-13 | Ulmwh (ultra-low-molecular weight heparin) for treating asthma |
UA98020876A UA62919C2 (en) | 1995-08-18 | 1996-08-13 | Method (variants) and composition for treating asthma |
ARP960103997A AR003271A1 (es) | 1995-08-18 | 1996-08-15 | Una composicion farmaceutica para el tratamiento del asma inducido por un antigeno y uso de la heparina de peso molecular ultra bajo para la preparación de dicha composicón farmacéutica. |
US08/904,565 US5980865A (en) | 1995-08-18 | 1997-08-04 | Method for treating late phase allergic reactions and inflammatory diseases |
MXPA/A/1998/001165A MXPA98001165A (es) | 1995-08-18 | 1998-02-11 | Metodo y composicion para el tratamiento del asma |
HK98106409A HK1007060A1 (en) | 1995-08-18 | 1998-06-24 | Ulmwh (ultra-low-molecular weight heparin) for treating asthma. |
US09/304,814 US6193957B1 (en) | 1995-08-18 | 1999-05-04 | Pharmaceutical compositions for treating late phase allergic reactions and inflammatory diseases |
NZ337996A NZ337996A (en) | 1995-08-18 | 1999-09-23 | Method for treating asthma by administering ultra-low molecular weight heparins (ULMWH) by inhalent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/516,786 US5690910A (en) | 1995-08-18 | 1995-08-18 | Method for treating asthma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/904,565 Continuation-In-Part US5980865A (en) | 1995-08-18 | 1997-08-04 | Method for treating late phase allergic reactions and inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
US5690910A true US5690910A (en) | 1997-11-25 |
Family
ID=24057086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/516,786 Expired - Fee Related US5690910A (en) | 1995-08-18 | 1995-08-18 | Method for treating asthma |
Country Status (22)
Country | Link |
---|---|
US (1) | US5690910A (es) |
EP (1) | EP0844869B1 (es) |
JP (1) | JP3263723B2 (es) |
KR (1) | KR100451901B1 (es) |
AR (1) | AR003271A1 (es) |
AT (1) | ATE300938T1 (es) |
AU (1) | AU701691B2 (es) |
CA (1) | CA2229060A1 (es) |
CZ (1) | CZ292134B6 (es) |
DE (1) | DE69635023T2 (es) |
DK (1) | DK0844869T3 (es) |
ES (1) | ES2244974T3 (es) |
HK (1) | HK1007060A1 (es) |
HU (1) | HUP9901614A3 (es) |
IL (1) | IL123166A (es) |
NZ (2) | NZ315275A (es) |
PL (1) | PL186912B1 (es) |
PT (1) | PT844869E (es) |
SK (1) | SK282759B6 (es) |
UA (1) | UA62919C2 (es) |
WO (1) | WO1997006783A1 (es) |
ZA (1) | ZA966838B (es) |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980865A (en) * | 1995-08-18 | 1999-11-09 | Baker Norton Pharmaceuticals, Inc. | Method for treating late phase allergic reactions and inflammatory diseases |
WO2001093846A2 (en) * | 2000-05-23 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
WO2006026998A1 (en) | 2004-09-10 | 2006-03-16 | Pharmaorigin Aps | Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis |
US20070065373A1 (en) * | 2003-09-15 | 2007-03-22 | Vectura Ltd. | Mucoactive agents for treating a pulmonary disease |
CN100352448C (zh) * | 1998-10-30 | 2007-12-05 | Ivax研究公司 | 用于预防药物耐受性的用途和组合物 |
US20100298260A1 (en) * | 2007-11-02 | 2010-11-25 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
US20100316640A1 (en) * | 2007-11-02 | 2010-12-16 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
US20100324276A1 (en) * | 2007-11-02 | 2010-12-23 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
US20110136757A1 (en) * | 2009-12-03 | 2011-06-09 | Opko Health, Inc. | Hypersulfated disaccharide formulations |
US8071570B2 (en) | 2002-10-10 | 2011-12-06 | Aventis Pharma S.A. | Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
US8424518B2 (en) | 2008-06-13 | 2013-04-23 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
CN103269585A (zh) * | 2010-10-29 | 2013-08-28 | Opko健康公司 | 治疗弹性蛋白酶相关病症的超硫酸化双糖 |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9346766B2 (en) | 2004-08-20 | 2016-05-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US9358352B2 (en) | 2008-06-13 | 2016-06-07 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9387256B2 (en) | 2010-04-16 | 2016-07-12 | Momenta Pharmaceuticals, Inc. | Tissue targeting |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US10017585B2 (en) | 2010-06-17 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
US10016449B2 (en) | 2013-05-28 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US10829509B2 (en) | 2016-08-16 | 2020-11-10 | Opko Pharmaceuticals, Llc | Pure heptasulfated disaccharides having improved oral bioavailability |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7056504B1 (en) | 1998-08-27 | 2006-06-06 | Massachusetts Institute Of Technology | Rationally designed heparinases derived from heparinase I and II |
SI1124563T1 (en) * | 1998-10-30 | 2005-02-28 | Ivax Research, Inc. | Methods and compositions for the prevention of tolerance to bronchodilators |
CA2402160C (en) | 2000-03-08 | 2012-02-14 | Massachusetts Institute Of Technology | Heparinase iii and uses thereof |
WO2002023190A2 (en) | 2000-09-12 | 2002-03-21 | Massachusetts Institute Of Technology | Methods and products related to low molecular weight heparin |
AU2002224408B2 (en) * | 2000-10-18 | 2007-08-23 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
RU2528093C2 (ru) * | 2010-07-21 | 2014-09-10 | Олег Ильич Эпштейн | Фармацевтическая композиция и способ лечения острых и хронических заболевания дыхательной системы и синдрома кашля |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2200771T3 (es) * | 1991-06-10 | 2004-03-16 | Schering Corporation | Formulaciones en aerosol no clorofluorocarbonadas. |
AU3938093A (en) * | 1992-04-02 | 1993-11-08 | Baker Norton Pharmaceuticals, Inc. | Method and composition for treating antigen-induced and exercise-induced asthma |
-
1995
- 1995-08-18 US US08/516,786 patent/US5690910A/en not_active Expired - Fee Related
-
1996
- 1996-08-13 ES ES96926952T patent/ES2244974T3/es not_active Expired - Lifetime
- 1996-08-13 DE DE69635023T patent/DE69635023T2/de not_active Expired - Lifetime
- 1996-08-13 AT AT96926952T patent/ATE300938T1/de active
- 1996-08-13 JP JP50942897A patent/JP3263723B2/ja not_active Expired - Lifetime
- 1996-08-13 NZ NZ315275A patent/NZ315275A/xx not_active IP Right Cessation
- 1996-08-13 IL IL12316696A patent/IL123166A/en not_active IP Right Cessation
- 1996-08-13 EP EP96926952A patent/EP0844869B1/en not_active Expired - Lifetime
- 1996-08-13 ZA ZA9606838A patent/ZA966838B/xx unknown
- 1996-08-13 HU HU9901614A patent/HUP9901614A3/hu unknown
- 1996-08-13 KR KR10-1998-0701167A patent/KR100451901B1/ko not_active IP Right Cessation
- 1996-08-13 AU AU66945/96A patent/AU701691B2/en not_active Expired
- 1996-08-13 PT PT96926952T patent/PT844869E/pt unknown
- 1996-08-13 PL PL96324970A patent/PL186912B1/pl unknown
- 1996-08-13 UA UA98020876A patent/UA62919C2/uk unknown
- 1996-08-13 SK SK172-98A patent/SK282759B6/sk not_active IP Right Cessation
- 1996-08-13 CA CA002229060A patent/CA2229060A1/en not_active Abandoned
- 1996-08-13 WO PCT/US1996/013133 patent/WO1997006783A1/en active IP Right Grant
- 1996-08-13 DK DK96926952T patent/DK0844869T3/da active
- 1996-08-13 CZ CZ1998481A patent/CZ292134B6/cs not_active IP Right Cessation
- 1996-08-15 AR ARP960103997A patent/AR003271A1/es not_active Application Discontinuation
-
1998
- 1998-06-24 HK HK98106409A patent/HK1007060A1/xx not_active IP Right Cessation
-
1999
- 1999-09-23 NZ NZ337996A patent/NZ337996A/en not_active IP Right Cessation
Non-Patent Citations (18)
Title |
---|
Ahmed, et al., American Physiol. Soc. , pp. 1492 1498 (1993). * |
Ahmed, et al., American Physiol. Soc., pp. 1492-1498 (1993). |
Ahmed, et al., American Physiol. Soc., pp. 893 901 (1994). * |
Ahmed, et al., American Physiol. Soc., pp. 893-901 (1994). |
Ahmed, et al., N. Engl. J. Med. , vol. 329, pp. 90 95 (1993). * |
Ahmed, et al., N. Engl. J. Med., vol. 329, pp. 90-95 (1993). |
Ahmed, et. al., Am. Rev. Respir. Dis. , vol. 145, pp. 566 570 (1992). * |
Ahmed, et. al., Am. Rev. Respir. Dis., vol. 145, pp. 566-570 (1992). |
Ahmed, Resp. Drug Delivery IV , pp. 55 63 (1994). * |
Ahmed, Resp. Drug Delivery IV, pp. 55-63 (1994). |
Ashkin, et al., Am. Rev. Resp. Dis. , vol. 147, No. 4, p. A660 (1993). * |
Ashkin, et al., Am. Rev. Resp. Dis., vol. 147, No. 4, p. A660 (1993). |
Karnovsky et al., Airwaves and Vascular Remodelling , pp. 45 69 (1994). * |
Karnovsky et al., Airwaves and Vascular Remodelling, pp. 45-69 (1994). |
Lucio, et al., American Physiol. Soc. , pp. 1093 1101 (1992). * |
Lucio, et al., American Physiol. Soc., pp. 1093-1101 (1992). |
Page, Lancet , vol. 337, pp. 717 720 (1991). * |
Page, Lancet, vol. 337, pp. 717-720 (1991). |
Cited By (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980865A (en) * | 1995-08-18 | 1999-11-09 | Baker Norton Pharmaceuticals, Inc. | Method for treating late phase allergic reactions and inflammatory diseases |
US20020086852A1 (en) * | 1998-05-14 | 2002-07-04 | Cantor Jerome O. | Method for treating respiratory disorders associated with pulmonary elastic fiber injury |
CN100352448C (zh) * | 1998-10-30 | 2007-12-05 | Ivax研究公司 | 用于预防药物耐受性的用途和组合物 |
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
WO2001093846A2 (en) * | 2000-05-23 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
WO2001093846A3 (en) * | 2000-05-23 | 2002-05-23 | Univ Columbia | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US8071570B2 (en) | 2002-10-10 | 2011-12-06 | Aventis Pharma S.A. | Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
US20070065373A1 (en) * | 2003-09-15 | 2007-03-22 | Vectura Ltd. | Mucoactive agents for treating a pulmonary disease |
US7928089B2 (en) | 2003-09-15 | 2011-04-19 | Vectura Limited | Mucoactive agents for treating a pulmonary disease |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US9346766B2 (en) | 2004-08-20 | 2016-05-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US10130685B2 (en) | 2004-08-23 | 2018-11-20 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US20070060517A1 (en) * | 2004-09-10 | 2007-03-15 | Lars Heslet | Methods for preventing and treating local tracheal, bronchial or alveolar bleeding or hemoptysis |
US8431535B2 (en) | 2004-09-10 | 2013-04-30 | Hoiberg A/S | Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis |
US7807639B2 (en) | 2004-09-10 | 2010-10-05 | Pharmaorigin Asp | Methods for preventing and treating local tracheal, bronchial or alveolar bleeding or hemoptysis |
US20070258971A1 (en) * | 2004-09-10 | 2007-11-08 | Pharmaorgin Aps | Methods for Treating Local Tracheal, Bronchial or Alveolar Bleeding or Hemoptysis |
WO2006026998A1 (en) | 2004-09-10 | 2006-03-16 | Pharmaorigin Aps | Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis |
US9717689B2 (en) | 2005-09-14 | 2017-08-01 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9446001B2 (en) | 2005-09-14 | 2016-09-20 | Mannkind Corporation | Increasing drug affinity for crystalline microparticle surfaces |
US10143655B2 (en) | 2005-09-14 | 2018-12-04 | Mannkind Corporation | Method of drug formulation |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US10130581B2 (en) | 2006-02-22 | 2018-11-20 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
US9358252B2 (en) | 2007-11-02 | 2016-06-07 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
US9212233B2 (en) | 2007-11-02 | 2015-12-15 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
US20100298260A1 (en) * | 2007-11-02 | 2010-11-25 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
US20100316640A1 (en) * | 2007-11-02 | 2010-12-16 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
US20100324276A1 (en) * | 2007-11-02 | 2010-12-23 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
US9351992B2 (en) | 2007-11-02 | 2016-05-31 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
US10201672B2 (en) | 2008-06-13 | 2019-02-12 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9339615B2 (en) | 2008-06-13 | 2016-05-17 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9358352B2 (en) | 2008-06-13 | 2016-06-07 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9192675B2 (en) | 2008-06-13 | 2015-11-24 | Mankind Corporation | Dry powder inhaler and system for drug delivery |
US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
US8499757B2 (en) | 2008-06-13 | 2013-08-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
US9393372B2 (en) | 2008-06-13 | 2016-07-19 | Mannkind Corporation | Dry powder drug delivery system |
US9446133B2 (en) | 2008-06-13 | 2016-09-20 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8424518B2 (en) | 2008-06-13 | 2013-04-23 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9511198B2 (en) | 2008-06-13 | 2016-12-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10751488B2 (en) | 2008-06-13 | 2020-08-25 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US8636001B2 (en) | 2008-06-13 | 2014-01-28 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8912193B2 (en) | 2008-06-13 | 2014-12-16 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US10675421B2 (en) | 2008-06-20 | 2020-06-09 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9655850B2 (en) | 2008-12-29 | 2017-05-23 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US10172850B2 (en) | 2008-12-29 | 2019-01-08 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US20110136757A1 (en) * | 2009-12-03 | 2011-06-09 | Opko Health, Inc. | Hypersulfated disaccharide formulations |
US8546351B2 (en) | 2009-12-03 | 2013-10-01 | Opko Health, Inc. | Hypersulfated disaccharide formulations |
US9387256B2 (en) | 2010-04-16 | 2016-07-12 | Momenta Pharmaceuticals, Inc. | Tissue targeting |
US10017585B2 (en) | 2010-06-17 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
CN103269585B (zh) * | 2010-10-29 | 2016-12-21 | Opko健康公司 | 治疗弹性蛋白酶相关病症的超硫酸化双糖 |
CN103269585A (zh) * | 2010-10-29 | 2013-08-28 | Opko健康公司 | 治疗弹性蛋白酶相关病症的超硫酸化双糖 |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US10130709B2 (en) | 2011-06-17 | 2018-11-20 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US10258664B2 (en) | 2011-10-24 | 2019-04-16 | Mannkind Corporation | Methods and compositions for treating pain |
US9610351B2 (en) | 2011-10-24 | 2017-04-04 | Mannkind Corporation | Methods and compositions for treating pain |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US10016449B2 (en) | 2013-05-28 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US10829509B2 (en) | 2016-08-16 | 2020-11-10 | Opko Pharmaceuticals, Llc | Pure heptasulfated disaccharides having improved oral bioavailability |
Also Published As
Publication number | Publication date |
---|---|
CZ292134B6 (cs) | 2003-08-13 |
HUP9901614A3 (en) | 2000-04-28 |
DK0844869T3 (da) | 2005-12-12 |
JPH11511196A (ja) | 1999-09-28 |
ZA966838B (en) | 1997-02-19 |
NZ337996A (en) | 2001-04-27 |
WO1997006783A1 (en) | 1997-02-27 |
IL123166A (en) | 2002-07-25 |
KR19990037688A (ko) | 1999-05-25 |
MX9801165A (es) | 1998-07-31 |
EP0844869B1 (en) | 2005-08-03 |
ATE300938T1 (de) | 2005-08-15 |
UA62919C2 (en) | 2004-01-15 |
DE69635023D1 (de) | 2005-09-08 |
CA2229060A1 (en) | 1997-02-27 |
HUP9901614A2 (hu) | 1999-09-28 |
ES2244974T3 (es) | 2005-12-16 |
EP0844869A4 (en) | 2003-04-09 |
SK282759B6 (sk) | 2002-12-03 |
EP0844869A1 (en) | 1998-06-03 |
AU701691B2 (en) | 1999-02-04 |
SK17298A3 (en) | 1998-09-09 |
HK1007060A1 (en) | 1999-04-01 |
CZ48198A3 (cs) | 1998-11-11 |
NZ315275A (en) | 2000-01-28 |
JP3263723B2 (ja) | 2002-03-11 |
AR003271A1 (es) | 1998-07-08 |
AU6694596A (en) | 1997-03-12 |
DE69635023T2 (de) | 2006-05-24 |
KR100451901B1 (ko) | 2005-09-12 |
IL123166A0 (en) | 1998-09-24 |
PL324970A1 (en) | 1998-06-22 |
PT844869E (pt) | 2005-10-31 |
PL186912B1 (pl) | 2004-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5690910A (en) | Method for treating asthma | |
US5980865A (en) | Method for treating late phase allergic reactions and inflammatory diseases | |
JP4585121B2 (ja) | 薬剤療法に対する寛容を予防するための方法と組成物 | |
WO1993019734A1 (en) | Method and composition for treating antigen-induced and exercise-induced asthma | |
ES2258145T3 (es) | Disacaridos hipersulfatados y procedimientos para la utilizacion de los mismos en el tratamiento de las inflamaciones. | |
RU2179445C2 (ru) | Способ и композиция для лечения астмы | |
AU775161B2 (en) | Method and compositions for treating late phase allergic reactions and inflammatory diseases | |
Chin et al. | Reversal of bronchial obstruction in children with mild stable asthma by aerosolized furosemide | |
MXPA98001165A (es) | Metodo y composicion para el tratamiento del asma | |
MXPA00000992A (es) | "composiciones para el tratamiento de reacciones alergicas en fase tardia y enfermedades inflamatorias" | |
CZ2000426A3 (cs) | Farmaceutický přípravek k léčení pozdní fáze alergické reakce a zánětlivé nemoci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAKER NORTON PHARMACEUTICALS, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AHMED, TAHIR;BRODER, SAMUEL;WHISNANT, JOHN K.;REEL/FRAME:007818/0330;SIGNING DATES FROM 19950815 TO 19950817 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20011125 |